RhumbLine Advisers’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-72,459
| Closed | -$65.9K | – | 4197 |
|
|
2025
Q1 | $65.9K | Sell |
72,459
-4,792
| -6% | -$4.36K | ﹤0.01% | 3505 |
|
|
2024
Q4 | $214K | Buy |
77,251
+434
| +0.6% | +$1.2K | ﹤0.01% | 3159 |
|
|
2024
Q3 | $402K | Sell |
76,817
-187
| -0.2% | -$978 | ﹤0.01% | 2853 |
|
|
2024
Q2 | $343K | Buy |
77,004
+13,867
| +22% | +$61.8K | ﹤0.01% | 2923 |
|
|
2024
Q1 | $484K | Buy |
63,137
+2,843
| +5% | +$21.8K | ﹤0.01% | 2686 |
|
|
2023
Q4 | $257K | Buy |
60,294
+14,365
| +31% | +$61.2K | ﹤0.01% | 3057 |
|
|
2023
Q3 | $193K | Buy |
45,929
+2,518
| +6% | +$10.6K | ﹤0.01% | 3176 |
|
|
2023
Q2 | $242K | Buy |
+43,411
| New | +$242K | ﹤0.01% | 3139 |
|
|
2022
Q2 | – | Sell |
-12,890
| Closed | -$53K | – | 3167 |
|
|
2022
Q1 | $53K | Sell |
12,890
-174
| -1% | -$715 | ﹤0.01% | 2968 |
|
|
2021
Q4 | $89K | Sell |
13,064
-398
| -3% | -$2.71K | ﹤0.01% | 2952 |
|
|
2021
Q3 | $156K | Buy |
13,462
+675
| +5% | +$7.82K | ﹤0.01% | 2945 |
|
|
2021
Q2 | $218K | Buy |
+12,787
| New | +$218K | ﹤0.01% | 2902 |
|